KFSH’s integrated framework connects medical genomics, an internationally accredited precision medicine laboratory, computational sciences, and translational research, creating a system where ...

Like the billions of public dollars for the private spa contract at Ontario Place, millions for the private jet, half-a-billion subsidizing corner store booze and so on, the Coalition is warning that ...

Depressive disorders and MND both affect a significant portion of people living with HIV in the United States and worldwide, even when their HIV is successfully managed and treated with antiretroviral ...

Ex-U.S. rights realigned under amendment to distribution agreement with Fresenius Medical Care - - Positions Humacyte to advance discussions with corporate partners regarding in ...

Medicana Health Group has launched a new HPV vaccination and cervical cancer awareness campaign designed to expand prevention, strengthen public understanding, and reinforce trust in evidence-based ...

Kyowa Kirin Co., Ltd. (TSE: 4151, “Kyowa Kirin”) and Kura Oncology, Inc. (Nasdaq: KURA, “Kura”) today announced the first patient has been dosed in a Japanese Phase 2 registrational clinical trial ...

In celebration of DNA DAY™, A.D.A.M. Innovations Co. (Japanese corporate name Genesis Healthcare Co.) today announced a major update to GeneLife GeneAI Forecast, expanding the service to 15 AI-powered ...

TOKYO, April 24, 2026 (GLOBE NEWSWIRE) -- A.D.A.M. Innovations Co. (Japanese corporate name: Genesis Healthcare Co.) today announced GeneLock™, a new genomic security platform designed to help secure ...

A collaboration with Virginia Tech supports recognizing remission as a treatment outcome—capturing symptoms, quality of life, and functional outcomes—beyond abstinence alone Of all MOUD, monthly ...

Following completion of the Arrangement, Jushi expects the Nevada Common Stock will be listed for trading on the Canadian Securities Exchange and quoted on the OTCQX in place of the Subordinate Voting ...

Alvotech (NASDAQ: ALVO; ALVO-SDB) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that ...

Sanofi’s Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses. Recommendation based on the HERCULES ...